Qualitest confirms launch of generic Singulair Tablets for asthma and allergic rhinitis

NewsGuard 100/100 Score
Aug 6 2012

Qualitest Pharmaceuticals today confirmed that it has launched a generic version of Singulair (montelukast sodium) Tablets and Chewable Tablets, following the expiration of the last patent that provides Merck U.S. market exclusivity.  Qualitest will begin shipping the product immediately.   Montelukast Sodium Tablets are labeled for use in treating symptoms of asthma and allergic rhinitis. 

The total combined sales for Montelukast Sodium Tablets and Chewables in the U.S. for the 12 months ending June 30, 2012, were approximately $4.9 billion, according to IMS Health.

Source:

Qualitest Pharmaceuticals

Posted in: Medical Condition News | Medical Patent News | Pharmaceutical News

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

SARS-COV-2 infection not linked to increased risk of asthma development in pediatric patients
Newly discovered cause for asthma sparks hope for treatment
Asthma attacks cause airway damage beyond inflammation, research shows
Higher zinc intake linked to lower asthma risk in overweight kids
Air pollution in Austin neighborhoods raises asthma-related ER visits, study finds
Poorly controlled asthma linked to excessive greenhouse gas emissions, study finds
Multiple atmospheric pollutants may be triggering asthma symptoms among children
Early exposure to air pollution tied to higher childhood asthma risk, disparities worsen impact

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses